Stockreport

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center [Yahoo! Finance]

Virios Therapeutics, Inc.  (VIRI) 
PDF - Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients, highlighting potential for antiviral therapy to treat fatigue and other Long-COVI [Read more]